Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed July 2026
Key Takeaways
- The landmark trials demonstrate slowing of disease progression, not reversal of established cardiac amyloid.
- ATTR-ACT (tafamidis) and ATTRibute-CM (acoramidis) reduced cardiovascular mortality and cardiovascular-related hospitalization versus placebo.
- Assessment of cumulative cardiovascular event burden matters more than single-event analyses alone.
- Interpretation of trial findings depends on accurate phenotyping and long-term treatment persistence.
What the Landmark ATTR-CM Trials Established
The landmark trials established that transthyretin stabilizers can change the course of confirmed ATTR-CM. In ATTR-ACT, tafamidis reduced cardiovascular mortality and cardiovascular-related hospitalization compared with placebo; in ATTRibute-CM, acoramidis improved a hierarchical outcome built on death and cardiovascular hospitalization. Because both studies were placebo-controlled rather than head-to-head trials, their findings should be interpreted independently and should not be used for direct comparisons between therapies.
Why the Signal Is Disease Slowing Rather Than Reversal
The treatment benefit reflects slowing of disease progression rather than reversal of established disease. Stabilizers bind transthyretin and reduce the formation of new amyloid, but they don't dissolve or remove fibrils already deposited in the heart. That mechanism of action defines the expected therapeutic effect. Earlier initiation of therapy may maximize the slow disease progression before extensive myocardial damage has occurred, which is why earlier, confirmed treatment is emphasized and why claims of disease reversal overstates what the evidence supports.
Why Cumulative Event Burden Changes Interpretation
Assessment of cumulative cardiovascular event burden is important because patients with ATTR-CM commonly experience recurrent cardiovascular events. Unlike first-event analyses, cumulative-event analyses capture subsequent events, providing a more comprehensive assessment of disease burden and treatment effect over time.
Why Phenotype Quality and Persistence Bound the Landmark Signal
The treatment benefit observed in the landmark trials should be interpreted within the context of the enrolled study population that produced it: accurate phenotyping, subtype confirmation, and sustained treatment. Specialized-center practice and real-world persistence experience both show that treatment benefit may be reduced when diagnosis is uncertain or therapy is interrupted. Landmark evidence is most applicable when applied to patients with confirmed ATTR-CM who receive continuous treatment—the same population on which the evidence was built. This interpretation is supported by real-world evidence.
Clinical Decision Point
The landmark evidence supports treating confirmed ATTR-CM to slow progression and reduce cumulative cardiovascular burden while setting the expectation that established injury won't reverse. Clinical benefit depends on securing the diagnosis, treating early enough that modifiable disease remains, and sustaining therapy long enough for the long-term clinical outcomes rather than short-term assessment at a single follow-up visit.
Frequently Asked Questions
What do the landmark ATTR-CM trials actually show?
ATTR-ACT for tafamidis and ATTRibute-CM for acoramidis show that transthyretin stabilizers reduced cardiovascular mortality and cardiovascular-related hospitalization versus placebo in confirmed ATTR-CM.
Do these therapies reverse cardiac amyloid?
No. They slow the formation of new amyloid but don't clear deposits already in the myocardium, so the benefit is slowed progression rather than reversal.
Why does cumulative event burden matter?
Cumulative event burden matters because the disease causes repeated events. Assessment of cumulative cardiovascular events over time reflects the overall disease burden better than a first-event-only view and provides a more comprehensive assessment of treatment benefit.
Part of the Spotlight On ATTR-CM resource center.
References:
- ATTR-ACT: Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. New England Journal of Medicine
- ATTRibute-CM: Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. New England Journal of Medicine
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart
- Effect of acoramidis on recurrent and cumulative cardiovascular outcomes in ATTR-CM (ATTRibute-CM exploratory analysis). Journal of the American College of Cardiology
- Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance: Journal of the American College of Cardiology
- Best Practices in Specialized Amyloidosis Centers in the United States. Clinical Medicine Insights: Cardiology
- Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with ATTR-CM and/or receiving tafamidis prescriptions. Journal of Managed Care & Specialty Pharmacy
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.